Acorda Therapeutics, Inc. (ACORQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ACORQ representa a Acorda Therapeutics, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 42/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Acorda Therapeutics, Inc. (ACORQ) Resumen de Asistencia Médica y Tuberías
Acorda Therapeutics, Inc. develops and commercializes therapies for neurological disorders, including Ampyra for multiple sclerosis and Inbrija for Parkinson's disease. Facing financial challenges, the company filed for Chapter 11 bankruptcy in 2024 and now operates in the OTC market, impacting its market capitalization and investor accessibility.
Tesis de Inversión
Investing in Acorda Therapeutics, Inc. (ACORQ) presents substantial risks due to its Chapter 11 bankruptcy filing in April 2024. The company's future hinges on the successful restructuring of its debt and operations. Key value drivers include the continued sales of Ampyra and Inbrija, though these are subject to market competition and pricing pressures. Growth catalysts are limited given the bankruptcy status, but potential restructuring plans and strategic asset sales could unlock value. Investors should closely monitor the bankruptcy proceedings and any announcements regarding the company's long-term strategy. The company's negative profit margin of -215.0% and its current trading status on the OTC market further underscore the high-risk nature of this investment.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.00B reflects the company's distressed financial state following its Chapter 11 filing.
- Profit margin of -215.0% indicates significant losses and operational challenges.
- Gross margin of 60.9% suggests that the company's core products retain some profitability before accounting for operating expenses and debt servicing.
- Beta of 1.69 indicates higher volatility compared to the broader market, reflecting the uncertainty surrounding the company's future.
- Chapter 11 bankruptcy filing on April 1, 2024, represents a critical turning point for the company's operations and financial structure.
Competidores y Pares
Fortalezas
- Established products in the market for neurological disorders (Ampyra and Inbrija).
- Collaboration agreement with Biogen Inc. for Ampyra.
- Gross margin of 60.9% indicates potential profitability at the product level.
Debilidades
- Chapter 11 bankruptcy filing indicates severe financial distress.
- Negative profit margin of -215.0% reflects significant losses.
- High debt burden and ongoing restructuring efforts.
- Trading on the OTC market limits liquidity and investor access.
Catalizadores
- Upcoming: Bankruptcy court decisions regarding restructuring plan.
- Upcoming: Potential asset sales or licensing agreements.
- Ongoing: Continued sales of Ampyra and Inbrija.
- Ongoing: Efforts to reduce operating expenses and improve efficiency.
Riesgos
- Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.
- Potential: Generic competition for Ampyra and Inbrija.
- Potential: Pricing pressures and reimbursement challenges.
- Potential: Regulatory hurdles and delays in drug approvals.
- Ongoing: Limited liquidity and price volatility due to OTC trading.
Oportunidades de crecimiento
- Restructuring and Debt Resolution: Acorda's primary growth opportunity lies in successfully restructuring its debt and emerging from Chapter 11 bankruptcy. A favorable restructuring plan could alleviate financial pressures and allow the company to focus on its core products, Ampyra and Inbrija. The timeline for this is dependent on the bankruptcy court's decisions, but a resolution within the next 12-18 months is crucial for the company's survival.
- Strategic Asset Sales: Acorda could explore selling non-core assets or licensing agreements to generate capital and streamline operations. This could involve divesting certain product lines or partnering with other pharmaceutical companies to expand the market reach of its existing therapies. The success of this strategy depends on identifying suitable assets and securing favorable terms, with potential deals materializing within the next 6-12 months.
- Expansion of Inbrija Market: Despite its financial challenges, Acorda could focus on expanding the market for Inbrija, its inhaled levodopa treatment for Parkinson's disease. This could involve increasing awareness among physicians and patients, conducting further clinical trials to support new indications, and exploring partnerships to expand its distribution network. The market for Parkinson's disease treatments is growing, presenting a significant opportunity for Inbrija.
- Geographic Expansion: While facing bankruptcy, Acorda could explore opportunities to expand its geographic reach, particularly in emerging markets where there is unmet need for neurological disorder treatments. This could involve partnering with local distributors or licensing its products to companies with established market presence. However, this strategy would require significant investment and careful market analysis.
- New Product Development: Although financially constrained, Acorda could invest in developing new therapies for neurological disorders. This could involve focusing on early-stage research and development projects or acquiring promising drug candidates from other companies. However, this strategy is highly risky and would require significant capital investment, making it a longer-term growth opportunity.
Oportunidades
- Successful restructuring of debt and emergence from Chapter 11.
- Strategic asset sales to generate capital.
- Expansion of Inbrija market and potential new indications.
- Geographic expansion into emerging markets.
Amenazas
- Generic competition for Ampyra and Inbrija.
- Pricing pressures and reimbursement challenges.
- Regulatory hurdles and potential delays in drug approvals.
- Uncertainty surrounding the bankruptcy proceedings and potential liquidation.
Ventajas competitivas
- Patent protection for its key products, such as Ampyra and Inbrija, provides a degree of market exclusivity.
- Established relationships with healthcare providers and distributors.
- Brand recognition and reputation in the neurological disorder treatment market.
Acerca de ACORQ
Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Pearl River, New York. The company focuses on developing and commercializing therapies for neurological disorders. Its primary products include Ampyra (dalfampridine), an oral medication designed to improve walking in adults with multiple sclerosis, and Inbrija, an inhaled levodopa formulation used for the intermittent treatment of OFF periods in individuals with Parkinson's disease who are already being treated with a carbidopa/levodopa regimen. Acorda also markets Ampyra as Fampyra in Europe, Asia, and the Americas through partnerships. A significant collaboration for Acorda is its license agreement with Biogen Inc. for the development and commercialization of Ampyra. However, on April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York, reflecting substantial financial distress. This event has significantly altered the company's operational and financial landscape.
Qué hacen
- Develops and commercializes therapies for neurological disorders.
- Markets Ampyra (dalfampridine) to improve walking in adults with multiple sclerosis.
- Markets Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease.
- Sells Ampyra as Fampyra in Europe, Asia, and the Americas through partnerships.
- Collaborates with Biogen Inc. for the development and commercialization of Ampyra.
- Navigates regulatory approval processes for its pharmaceutical products.
Modelo de Negocio
- Develops pharmaceutical products for neurological disorders.
- Commercializes and markets these products directly or through partnerships.
- Generates revenue through sales of its pharmaceutical products, primarily Ampyra and Inbrija.
Contexto de la Industria
Acorda Therapeutics operates within the specialty pharmaceutical sector, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for neurological disorder treatments is substantial, driven by an aging population and increasing prevalence of conditions like multiple sclerosis and Parkinson's disease. However, the industry is also marked by patent expirations, generic competition, and pricing pressures. Acorda's bankruptcy reflects the challenges faced by smaller pharmaceutical companies in sustaining profitability and managing debt in this environment. Competitors like CBDHF, CHCR, GDBYF, GENN, and GNBT also operate in this space, facing similar market dynamics.
Clientes Clave
- Adults with multiple sclerosis who use Ampyra to improve walking.
- People with Parkinson's disease treated with a carbidopa/levodopa regimen who use Inbrija for OFF periods.
- Healthcare providers who prescribe Acorda's medications to their patients.
Finanzas
Gráfico e información
Precio de la acción de Acorda Therapeutics, Inc. (ACORQ): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ACORQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ACORQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ACORQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ACORQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Ron Cohen
CEO
Ron Cohen has served as the CEO of Acorda Therapeutics, Inc. He has extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies focused on neurological disorders. Cohen's expertise spans drug development, commercialization, and corporate strategy. He has been instrumental in guiding Acorda through various stages of growth and challenges, including the development and launch of Ampyra and Inbrija. His leadership is critical as the company navigates its Chapter 11 restructuring.
Historial: Under Ron Cohen's leadership, Acorda Therapeutics successfully developed and commercialized Ampyra and Inbrija. He oversaw the company's collaboration with Biogen Inc. for Ampyra. However, his tenure also saw the company face significant financial challenges, culminating in the Chapter 11 bankruptcy filing in April 2024. The success of the restructuring efforts will be a key indicator of his leadership during this critical period.
Información del mercado OTC de ACORQ
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acorda Therapeutics does not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often face significant financial distress, regulatory issues, or lack of transparency. Trading on the OTC Other tier typically involves higher risks due to limited information and potential for manipulation compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity and potential for price volatility due to OTC trading.
- Lack of consistent financial reporting and transparency.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Chapter 11 bankruptcy proceedings create significant uncertainty.
- Potential for delisting and loss of investment.
- Review bankruptcy filings and court documents.
- Assess the company's restructuring plan and prospects for emerging from Chapter 11.
- Evaluate the company's remaining assets and potential for asset sales.
- Monitor news and press releases for updates on the company's financial condition.
- Consult with a financial advisor to assess the risks and potential rewards.
- Verify the company's legal and regulatory compliance.
- Understand the terms and conditions of trading OTC stocks.
- Existing products (Ampyra and Inbrija) with established market presence.
- Collaboration agreement with Biogen Inc. for Ampyra.
- History of operating as a publicly traded company prior to bankruptcy.
- Continued operations during the bankruptcy proceedings.
- Engagement of legal and financial advisors for the restructuring process.
ACORQ Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar ACORQ?
Acorda Therapeutics, Inc. (ACORQ) actualmente tiene una puntuación IA de 42/100, indicando puntuación baja. Fortaleza clave: Established products in the market for neurological disorders (Ampyra and Inbrija).. Riesgo principal a monitorear: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ACORQ?
ACORQ actualmente puntúa 42/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ACORQ?
Los precios de ACORQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ACORQ?
La cobertura de analistas para ACORQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ACORQ?
Las categorías de riesgo para ACORQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ACORQ?
La relación P/E para ACORQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ACORQ sobrevalorada o infravalorada?
Determinar si Acorda Therapeutics, Inc. (ACORQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ACORQ?
Acorda Therapeutics, Inc. (ACORQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change due to the ongoing bankruptcy proceedings.
- OTC market data may be limited or unreliable.